111 related articles for article (PubMed ID: 29490961)
1. Extent and cost of inappropriate use of tumour markers in patients with pulmonary disease: a multicentre retrospective study in Shanghai, China.
Zhang H; Song Y; Zhang X; Hu J; Yuan S; Ma J
BMJ Open; 2018 Feb; 8(2):e019051. PubMed ID: 29490961
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
3. An audit of tumour marker utilization in Greece.
Ntaios G; Hatzitolios A; Chatzinikolaou A; Karalazou P; Savopoulos C; Karamouzis M; Pidonia I
Eur J Intern Med; 2009 May; 20(3):e66-9. PubMed ID: 19393482
[TBL] [Abstract][Full Text] [Related]
4. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting.
Miravitlles M; Sicras A; Crespo C; Cuesta M; Brosa M; Galera J; Lahoz R; Lleonart M; Riera MI
Ther Adv Respir Dis; 2013 Jun; 7(3):139-50. PubMed ID: 23653458
[TBL] [Abstract][Full Text] [Related]
5. [Costs of the last hospitalization for patients with acute exacerbation of chronic obstructive pulmonary disease and patients with lung cancer].
Zhu ML; Cai BQ
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Apr; 32(4):258-61. PubMed ID: 19576037
[TBL] [Abstract][Full Text] [Related]
6. Tumor Marker Ordering: Do Not Lose Control: A Prospective Clinical Trial.
Ferraro S; Mozzi R; Panteghini M
Am J Clin Pathol; 2015 Oct; 144(4):649-58. PubMed ID: 26386087
[TBL] [Abstract][Full Text] [Related]
7. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].
Zemaitis M; Sakalauskas R; Malakauskas K; Muley T; Fischer JR; Lahm H
Medicina (Kaunas); 2005; 41(7):566-76. PubMed ID: 16062024
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function.
Lim JU; Kim K; Kim SH; Lee MG; Lee SY; Yoo KH; Lee SH; Jung KS; Rhee CK; Hwang YI
Int J Chron Obstruct Pulmon Dis; 2017; 12():2711-2721. PubMed ID: 28979113
[TBL] [Abstract][Full Text] [Related]
10. Adherence to Current COPD Guidelines in Turkey.
Turan O; Emre JC; Deniz S; Baysak A; Turan PA; Mirici A
Expert Opin Pharmacother; 2016; 17(2):153-8. PubMed ID: 26629809
[TBL] [Abstract][Full Text] [Related]
11. Three-year analysis of repeated laboratory tests for the markers total cholesterol, ferritin, vitamin D, vitamin B
Lanzoni M; Fornili M; Felicetta I; Maiavacca R; Biganzoli E; Castaldi S
J Eval Clin Pract; 2017 Jun; 23(3):654-661. PubMed ID: 28078809
[TBL] [Abstract][Full Text] [Related]
12. Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung.
Tsutani Y; Murakami S; Miyata Y; Nakayama H; Yoshimura M; Okada M
Eur J Cardiothorac Surg; 2015 Jun; 47(6):1022-6. PubMed ID: 25293403
[TBL] [Abstract][Full Text] [Related]
13. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
Friedman M; Menjoge SS; Anton SF; Kesten S
Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
[TBL] [Abstract][Full Text] [Related]
14. Effects of Integrated Case Payment on Medical Expenditure and Readmission of Inpatients with Chronic Obstructive Pulmonary Disease: A Nonrandomized, Comparative Study in Xi County, China.
Shi M; Wang J; Zhang L; Yan Y; Miao YD; Zhang X
Curr Med Sci; 2018 Jun; 38(3):558-566. PubMed ID: 30074226
[TBL] [Abstract][Full Text] [Related]
15. The relationship between tumor markers and pulmonary embolism in lung cancer.
Xiong W; Zhao Y; Xu M; Guo J; Pudasaini B; Wu X; Liu J
Oncotarget; 2017 Jun; 8(25):41412-41421. PubMed ID: 28575869
[TBL] [Abstract][Full Text] [Related]
16. Estimating the extent and economic impact of under and overdiagnosis of chronic obstructive pulmonary disease in primary care.
Spyratos D; Chloros D; Michalopoulou D; Sichletidis L
Chron Respir Dis; 2016 Aug; 13(3):240-6. PubMed ID: 26965221
[TBL] [Abstract][Full Text] [Related]
17. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness.
Arioli D; Pipino M; Boldrini E; Amateis E; Cristani A; Ventura P; Romagnoli E; De Santis MC; Zeneroli ML
Intern Emerg Med; 2007 Jun; 2(2):88-94. PubMed ID: 17622496
[TBL] [Abstract][Full Text] [Related]
18. Inappropriate practice in tumor marker requests at a university hospital in Western Saudi Arabia: A 3-year retrospective study.
Al-Mughales JA; Alahwal MS
Int J Biol Markers; 2020 Dec; 35(4):35-43. PubMed ID: 33158390
[TBL] [Abstract][Full Text] [Related]
19. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
